Skip to content

Comparing the effects of nebulized salbutamol epinephrine and 5 hypertonic saline on lowering theseverity of symptoms in infant

Comparison of the effect of salbutamol and inhaled epinephrine and 5% hypertonic saline on reducing the severity of symptoms and duration of hospitalization of infants with bronchiolitis

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20201101049210N1
Enrollment
45
Registered
2020-11-22
Start date
2020-11-25
Completion date
Unknown
Last updated
2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute bronchiolitis. Acute bronchiolitis

Interventions

Intervention 1: Recipients of inhaled salbutamol. Nebulizer treated with salbutamol 2.5 mg / kg every 4 hours via nebulizer and 48 to 24 hours after hospitalization. Intervention 2: Intervention group

Sponsors

Gorgan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Months to 24 Months

Inclusion criteria

Inclusion criteria: pediatric respiratory severity score>=4 history of lower respiratory tract infections wheezing,cough,cyanosis,spo2<90, fever age 2-24 month

Exclusion criteria

Exclusion criteria: drug reaction to salbutamol or epinephrine or hypertonic salin history of chronic cardiopulmonary disease preterm labor histroy of admision in age 0-2 month history of treatment with bronchodilator agents history of corticosteroid administration

Design outcomes

Primary

MeasureTime frame
Primary Outcome: Clinical signs including severity of respiratory distress, wheezing, skin color, general mood, respiratory rate, body temperature, and lung murmur. Timepoint: Before the intervention and 24 and 48 hours after the intervention. Method of measurement: Based on the score obtained from the pediatric respiratory severity score and observation.

Secondary

MeasureTime frame
The length of hospital stay is the number of days a patient receives medication, parenteral fluid, and oxygen for bronchiolitis. Timepoint: Once at the end of the treatment period. Method of measurement: Count the days the patient receives medication, parenteral fluid, and oxygen for bronchiolitis.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Ali Mosavikhosravi

Gorgan University of Medical Sciences

dr.ali.m363@gmail.com+98 17 3224 7622

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026